J. Venitz

发表

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

W. Figg, L. Jain, E. Gardner, 2008, Journal of pharmaceutical and biomedical analysis.

ResearchHypertension and hand-foot skin reactions related to VEGFR 2 genotype and improved clinical outcome following bevacizumab and sorafenib

G. Giaccone, E. Kohn, D. Venzon, 2015 .

Prediction of lidocaine tissue concentrations following different dose regimes during cardiac arrest using a physiologically based pharmacokinetic model.

J. Ornato, J. Venitz, J. Grillo, 2001, Resuscitation.

Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Corrigendum

D. Abraham, F. Musayev, M. Safo, 2011, Acta crystallographica. Section D, Biological crystallography.

Vzhe-039, a Novel Structurally-Enhanced Allosteric Hemoglobin Effector Inhibits Sickling of SS Erythrocytes In Vitro, and Exhibits Improved Pharmacologic Properties In Vivo

M. Safo, J. Venitz, M. Ghatge, 2016 .

Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states

P. Narayanaswami, D. Sanders, J. Venitz, 2015, Muscle & nerve.

Monitoring rFVIII prophylaxis dosing using global haemostasis assays

J. Venitz, D. Brophy, E. Martin, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Identifying a patient‐centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis

P. Narayanaswami, D. Sanders, J. Venitz, 2021, Muscle & nerve.

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.

J. Venitz, C. Dufton, A. Mandagere, 2009, British journal of clinical pharmacology.

Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

M. Allard, J. Venitz, C. Dufton, 2012, Journal of clinical pharmacology.

Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

J. Venitz, C. Dufton, A. Mandagere, 2008, Journal of clinical pharmacology.

Factors Involved in the Pharmacokinetics of COL‐3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies

M. Rudek, W. Figg, Y. Ando, 2003, Journal of clinical pharmacology.

Clinical Pharmacokinetics in the Elderly

P. Slattum, J. Venitz, 2004 .

Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.

F. Musayev, M. Safo, J. Venitz, 2020, Journal of medicinal chemistry.

Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.

F. Musayev, M. Safo, J. Venitz, 2018, Bioorganic & medicinal chemistry.

Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.

F. Musayev, M. Safo, J. Venitz, 2018, Acta crystallographica. Section D, Structural biology.

2‐Methoxyestradiol, a Promising Anticancer Agent

W. Figg, J. Venitz, N. Lakhani, 2003, Pharmacotherapy.

Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.

R. Yuan, J. Venitz, 2000, International journal of clinical pharmacology and therapeutics.

Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.

T. Veenstra, A. Sparreboom, Xia Xu, 2007, Journal of pharmaceutical sciences.

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

E. Sausville, J. Doroshow, B. Conley, 2006, Cancer Chemotherapy and Pharmacology.

Peptidoleukotriene (PLT) Release and Absorption from the Airways of the Isolated Perfused Guinea Pig Lung Following Chemical and Antigenic Challenge

J. Venitz, P. Byron, R. Kovelesky, 1999, Pharmaceutical Research.

In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.

Renishkumar R Delvadia, J. Venitz, P. Longest, 2016, Journal of aerosol medicine and pulmonary drug delivery.

Allosteric Modification of Oxygen Delivery by Hemoglobin

J. Wahr, J. Venitz, M. Gerber, 2001, Anesthesia and analgesia.

The Pharmacokinetics of Subcutaneous Enoxaparin in End‐Stage Renal Disease

J. Venitz, D. Brophy, T. Gehr, 2001, Pharmacotherapy.

Randomized discontinuation trial of sorafenib (BAY 43-9006)

L. Jain, J. Venitz, William D. Figg, II, 2006, Cancer biology & therapy.

The Pharmacokinetics of Enoxaparin Do Not Correlate With Its Pharmacodynamic Effect in Patients Receiving Dialysis Therapies

M. Carr, J. Venitz, D. Brophy, 2006, Journal of clinical pharmacology.

Using exposure-response and biomarkers to streamline early drug development.

J. Venitz, 2007, Ernst Schering Research Foundation workshop.

Surrogate Markers in Drug Development

J. Venitz, 2004 .

Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs.

J. Venitz, P. Lilly, P. Byron, 2011, Toxicology.

Assessment of 24-Hour Gastric pH Measurements in Trauma Patients Receiving Intravenous Famotidine by Intermittent Bolus versus Continuous Infusion Administration

J. Venitz, E. Gonzalez, H. Reines, 1994, The Annals of pharmacotherapy.

Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.

H. Fine, A. Sparreboom, W. Figg, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model.

M. Sakagami, J. Venitz, Sneha Dhapare, 2020, Biopharmaceutics & drug disposition.

A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.

E. Shaw, D. Abraham, K. Dusenbery, 2001, International journal of radiation oncology, biology, physics.

Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer

S. Steinberg, D. Draper, J. Wright, 2009, BJU international.

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

E. Sausville, A. Sparreboom, W. Figg, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers

J. Venitz, R. Polk, D. Israel, 1993, Antimicrobial Agents and Chemotherapy.

A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation.

M. Dewhirst, T. Secomb, B. Kavanagh, 2002, International journal of radiation oncology, biology, physics.

Determination of unbound L-tryptophan in human plasma using high-performance liquid chromatography with fluorescence detection.

J. Venitz, C. March, V. Jagannathan, 1995, Biomedical chromotography.

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.

R. Polzer, J. Venitz, S. Willavize, 1997, The Journal of antimicrobial chemotherapy.

Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials

J. Venitz, D. Gründemann, D. H. Sweet, 2013, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters

J. Venitz, D. H. Sweet, Aditi Mulgaonkar, 2012, Expert opinion on drug metabolism & toxicology.

Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.

A. Sparreboom, W. Figg, J. Venitz, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

J. Venitz, J. M. Davenport, P. Covington, 2015, Journal of clinical pharmacology.

Excretion of cefprozil into human breast milk

J. Venitz, K. Pittman, W. Shyu, 1992, Antimicrobial Agents and Chemotherapy.

Antiangiogenesis therapeutic strategies in prostate cancer.

G. Macpherson, W. Figg, J. Venitz, 2002 .

Evaluation of Truncated Areas in the Assessment of Bioequivalence of Immediate Release Formulations of Drugs with Long Half-Lives and of Cmax with Different Dissolution Rates

L. Lesko, J. Venitz, Pradeep M. Sathe, 1999, Pharmaceutical Research.

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

Boshi Huang, F. Musayev, M. Safo, 2020, Scientific Reports.

Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.

F. Musayev, M. Safo, J. Venitz, 2018, Acta crystallographica. Section D, Structural biology.

Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

F. Musayev, M. Safo, J. Venitz, 2017, Molecular pharmaceutics.

Quantitative assessment of the in-vitro binding kinetics of antisickling aromatic aldehydes with hemoglobin A: A universal HPLC-UV/Vis method to quantitate Schiff-base adduct formation.

Boshi Huang, M. Safo, J. Venitz, 2022, Journal of pharmaceutical and biomedical analysis.

Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry.

Mostafa H. Ahmed, M. Safo, J. Venitz, 2015, Biochemistry.

Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability

J. Venitz, P. Gerk, Neha Maharao, 2019, Biopharmaceutics & drug disposition.

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

S. Steinberg, E. Kohn, A. Sparreboom, 2006, Cancer biology & therapy.

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

D. Venzon, R. Danesi, W. Figg, 2009, Molecular Cancer Therapeutics.

Antiangiogenesis Therapeutic Strategies in Prostate Cancer

G. Macpherson, W. Figg, J. Venitz, 2004, Cancer and Metastasis Reviews.

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

S. Steinberg, E. Posadas, J. Wright, 2008, Clinical Cancer Research.

Pharmacokinetics and bioavailabilities of hymecromone in human volunteers

E. R. Garrett, J. Venitz, J. Cerda, 1993, Biopharmaceutics & drug disposition.

Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers

W. H. Barr, P. Slattum, J. Venitz, 1996, Journal of clinical pharmacology.

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

E. Sausville, J. Karp, A. Sparreboom, 2006, Investigational New Drugs.

Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

A. Sparreboom, W. Figg, J. Venitz, 2005, Molecular Pharmacology.

Clinical Pharmacology in the Older Adult

P. Slattum, J. Venitz, 2014 .

Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol

A. Sparreboom, W. Figg, J. Venitz, 2006, Anti-cancer drugs.

Matrix Metalloproteinase Inhibitors: Do They Have a Place in Anticancer Therapy?

M. Rudek, W. Figg, J. Venitz, 2002, Pharmacotherapy.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

G. Giaccone, E. Kohn, D. Mould, 2011, British journal of clinical pharmacology.

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

G. Giaccone, E. Kohn, D. Venzon, 2010, Journal of experimental & clinical cancer research : CR.

Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.

A. Sparreboom, W. Figg, J. Venitz, 2005, Rapid communications in mass spectrometry : RCM.

Preclinical Disposition (In Vitro) of Novel μ-Opioid Receptor Selective Antagonists

J. Venitz, Yunyun Yuan, Yan Zhang, 2011, Drug Metabolism and Disposition.

Discovery of second-generation NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization.

Shijun Zhang, J. Venitz, Yuqi Jiang, 2019, Journal of medicinal chemistry.

Comprar Appropriate Dose Selection - How to Optimize Clinical Drug Development | Venitz, J. | 9783540278672 | Springer

J. Venitz, W. Sittner, 2007 .

Appropriate Dose Selection - How to Optimize Clinical Drug Development

J. Venitz, W. Sittner, 2007 .

Comparison of Neural Network and Multiple Linear Regression as Dissolution Predictors#

J. Venitz, Pradeep M. Sathe, Pradeep M Sathe, 2003, Drug development and industrial pharmacy.

Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Hartmut Derendorf, Gerald Rhodes, Raymond Miller, 2000, Journal of clinical pharmacology.

Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.

A. Sparreboom, W. Figg, J. Venitz, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cumulative Organic Anion Transporter-Mediated Drug-Drug Interaction Potential of Multiple Components in Salvia Miltiorrhiza (Danshen) Preparations

J. Venitz, D. H. Sweet, Li Wang, 2014, Pharmaceutical Research.

Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.

G. Giaccone, B. Houk, W. Figg, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluation of the Vision Theophylline assays in the emergency department setting.

J. Venitz, A. Poklis, L. Edinboro, 1992, Annals of emergency medicine.

Pharmacogenetics of estrogen metabolism and transport in relation to cancer.

A. Sparreboom, W. Figg, J. Venitz, 2003, Current drug metabolism.

Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin.

J. Venitz, W. Garnett, G. Dimenna, 1994, The American journal of medicine.

Pharmacokinetics (PK) of intraveneous scopolamine (SCP) plus physostigmine (PHY) in healthy elderly male and female volunteers

J. Venitz, A. Men, 2004 .

Human Organic Cation Transporters ), 2 ), and ( ) as 1 Disposition Pathways for Fluoroquinolone Antimicrobials 2

J. Venitz, D. H. Sweet, Aditi Mulgaonkar, 2013 .

Transient Kinetic and Dynamic Interactions between Verapamil and Dofetilide, a Class III Antiarrhythmic

J. Venitz, B. Johnson, S. Cheng, 2001, Journal of clinical pharmacology.